Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

E.i. Dupont De Nemours and Company

The Dupont Merck Pharmaceutical Company

Albany Molecular Research, Inc.

Dupont Pharmaceuticals Company

Other

Roche Innovation Center Copenhagen A/s

Hoffmann-la Roche Inc.

Merck + Co., Inc.

Bristol-myers Squibb Pharma Corporation

The Scripps Research Institute

F. Hoffmann-la Roche Ag

Dupont Pharmaceuticals, Inc.

Bristol Meyers Squibb Company

Richard Eric Olson

Lorin Andrew Thompson

Ivar M McDonald

John E Macor

Hong Liu

Michael G Yang

Peter Hagedorn

Marianne Lerbech Jensen

Dalton King

Thomas P Maduskuie, Jr

Paul Joseph Gilligan

Upender Velaparthi

Jayakumar Sankara Warrier

Angela Marie Cacace

Nenghui Wang

Shuang Liu

Bruce Francis Molino

Qi Han

Stephen E Mercer

F Christopher Zusi

Christiana I Iwuagwu

Anja Mølhart Høg

Peter Guzzo

Min Ding

Robert G Gentles

Louis Stanley Chupak

Scott W Martin

Gary Avonn Cain

William Frietze

Chetan Padmakar Darne

Prasada Rao Jalagam

Saumya Roy

John Cuomo

James H Cook, Ii

Richard S Greenberg

Robert J Chorvat

Yong-Jin Wu

Annapurna Pendri

Rajagopal Bakthavatchalam

John E Starrett, Jr

Kenneth M Boy

Xiaofan Zheng

Kevin W Gillman

Bireshwar Dasgupta

Argyrios Georgios Arvanitis

James Peter Beck

Hasibur Rahaman

Yazhong Huang

Jere E Meredith, Jr

Dietmar A Seiffert

Robert A Mate

Wenge Cui

Dmitry S Zuev

Nino Devidze

Aruna Sambandam

Robert Zaczek

James K Loy

John Wityak

John S Tokarski

David Douglas Manning

Eric E Allen

Jianliang Shi

Lorin A Thompson, Iii

Yunhui Zhang

Niels Fisker Nielsen

Jason M Guernon

Matthew L Isherwood

Li Xu

Kassoum Nacro

Min Hu

Gopikishan Tonukunuru

Manjunatha Narayana Rao Kamble

Raju Mannoori

William R Ewing

Mimi Lifen Quan

Shaker Ahmed Mousa

Chu-Biao Xue

Douglas G Batt

Joseph B Santella

John J Duncia

Donald J Pinto

Martin D Eastgate

Lawrence R Marcin

Haiquan Fang

Parthasarathi Rajagopalan

Munir A Hussain

Bin Zheng

Phil Baran

Matthew D Hill

William Frank Degrado

Michael Anthony Schmidt

Andrew Charles Good

Bang-Chi Chen

Andrew J Tebben

Wei Deng

Srinivasan Thangathirupathy

Zhaoxing Meng

George N Karageorge

Imadul Islam

Huiping Zhang

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferatve disorders, such as cancer.

Substituted piperazine derivatives useful as T cell activators

The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.

Oligonucleotides for modulating Tau expression

The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; Y is CRor N; R, R, R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted bicyclic compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Naphthyridinone compounds useful as T cell activators

The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.

Methods of selecting therapeutic molecules

The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK&#x3b1;) and diacylglycerol kinase zeta (DGK&#x3b6;), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted naphthyridinone compounds useful as T cell activators

Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK&#x3b1;) and diacylglycerol kinase zeta (DGK&#x3b6;), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted pyridopyrimidinonyl compounds useful as T cell activators

Growing community of inventors

Wilmington, DE, United States of America

Richard Eric Olson